

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10244A		SERIAL NO. 09/528,978	
APPLICANT R. S. OBACH		FILING DATE March 21, 2000		GROUP 1617	

RECEIVED
 DEC 31 2003
 DEC 24 2003
 PATENT & TRADEMARK OFFICE
 PHOENIX CENTER 1800/295

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE							
SJD	US 5 1 6 6 2 0 7 A	11/24/92	Smith										
FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
SJD	1	D. Quellet, et al., "Antimicro Agent and Chemo", Vol. 42, No. 12, December 1998, pages 3107-3112.											
	/	MA Laurent-kenesi, et al., "Br. J. Clin Pharmacol.", PUBMED Abstract: 12959269; December 1993, 36(6) pages 531-8.											
	/	N. Yasui, et al., "Pharmacogenetics", PUBMED Abstract: 9352572, October 1997, 7(5) pages 369-374.											
	/	R. C. Halliday, et al., "An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems", Br. J. Clin Pharmacol., Oct. 1995, 40(4), pages 369-378, abstract (PMID: 8554939 (Medline)).											
	/	S. E. Ball, et al., "Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desimipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2", British Journal of Clinical Pharmacology, Vol. 43, Issue 6, June 1997, pages 619-626, abstract (PMID: 9205822 (Medline)).											
	/	S. H. Sindrup, et al., "The pharmacogenetics of codeine hypoalgesia", Pharmacogenetics, Vol. 5, Issue 6, December 1995, pages 335-346, abstract (PMID: 8845855 (Medline)).											
	/	B. A. Sproule, et al., "Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence", Clinical Pharmacokinetics, Vol. 33, Issue 6, December 1997, pages 454-471, abstract (PMID: 9435993 (Medline)).											
	/	J. B. Gordon, "SSRIs and St. John's Wort: possible toxicity?", American Family Physician, March 1, 1998, Vol. 57, Issue 5, pages 950-953, the whole document.											
	/	Chandra Prakash, et al., "Metabolism and excretion of a new anxiolytic drug candidate, CP-93393, in healthy male volunteers", Drug Metabolism and Disposition, Vol. 26, No. 5, pages 448-455, page 453, column 2-page 454, column 1.											
	/	J. S. Markowitz, et al., "Effect of St. John's Wort on Cytochrome P-450 2D6 and 3A4 Activity in Healthy Volunteers", Pharmacology Letters, January 21, 2000, Vol. 66, No. 9, pages 133-139, abstract.											
SJD		F. Broly, et al., "Effect of quinidine on the dextromorphan O-demethylase activity of microsomal fractions from human liver", Br. J. Clin Pharmacol., July 1989, 28(1), pages 29-36, abstract (PMID: 2775613 (Medline)).											
EXAMINER S. Jiang		DATE CONSIDERED <div style="font-size: 1.5em; font-family: cursive;">3/27/04</div>											

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 13 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PC10244A

SERIAL NO. 09/528,798⁹⁷⁸

APPLICANT R. S. Obach

FILING DATE March 21, 2000

GROUP unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL ATION
					yes no

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

B. Schmidt *et al.*, "Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation", Clin. Pharmacol. Ther., 38, 618 (1985)

K. Nakamura, *et al.*, "Oxidation of Histamine H1 Antagonist Mequitazine is Catalyzed by Cytochrome P450 2D6 in Human Liver Microsomes", J. Pharmacol. Exp. Ther., 284, 437-442 (1998)

H. Kamimura *et al.*, "Identification of cytochrome P450 isozymes involved in metabolism of the α_1 adrenoceptor blocker tamsulosin in human liver microsomes", Xenobiotica, 28, 909-22 (1998)

M. Yaïch *et al.*, "In vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans", Pharmacogen., 8, 449-51 (1998)

A.E. Mutlib *et al.*, "Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone, J. Pharmacol. Exp. Ther., 286, 1285-93 (1998)

R. Scott Orbach, *et al.*, "Cytochrome P4502D6 Catalyzes the O-Demethylation of the Psychoactive Alkaloid Ibogaine to 12-Hydroxyibogamine", Drug Metab. Dispos., 26, 764-8 (1998).

R.L. Voorman, *et al.*, Metabolism of Delavirdine, A Human Immunodeficiency virus Type-1 Reverse Transcriptase Inhibitor, by Microsomal Cytochrome P450 in Humans, Rats, and Other Species: Probable Involvement of CYP2D6 and CYP3A, Drug Metab. Dispos., 26, 631-9 (1998).

N. Brynne *et al.*, "Influence CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine", Clin. Pharmacol. Ther., 63, 529-39 (1998)

Rinshoyakon, 29, 231-38 (1998)

Z. Desta, *et al.*, "Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide¹, J. Pharmacol. Exp. Ther., 285, 428-37 (1998)

W. Kishimoto *et al.*, "Metabolism of Epinastine, a Histamine H1 Receptor Antagonist, in Human Liver Microsomes in Comparison with that of Terfenadine", Res. Comm. Md. Path. Pharmacol., 98, 273-92 (1997)

JUN 13 2003

JUN 13 2003

RECEIVED

TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10244A	SERIAL NO. 09/528,798 ⁹⁷⁸
		APPLICANT R. S. Obach	
		FILING DATE March 21, 2000	GROUP unknown

340	W.D. Paar <i>et al.</i> , "Polymorphic CYP2D6 mediates O-demethylation of the opoid analgesic tramadol", 12 <i>Eur. J. Clin. Pharm.</i> , 53, 235-239 (1997)
	E. Lessard <i>et al.</i> , "Role of CYP2D6 in the N-hydroxylation of procainamide", <i>Pharmacogenetics</i> , 7, 381-90 (1997);
	L.Y. Lin <i>et al.</i> , "Oxidation of Methamphetamine and Methylenedioxyamphetamine by CYP2D6", <i>Drug Metab. Dispos.</i> , 25, 1059-64 (1997)
	hangata Dehal <i>et al.</i> , "CYP2D6 Catalyzes Tamoxifen-Hydroxylation in Human Liver", <i>Cancer Res.</i> , 57, 3402-06 (1997)
	Y. Bottiger <i>et al.</i> , "Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans", <i>Br. J. Pharm.</i> , 42, 707-11 (1996)
	B. A. Hamelin <i>et al.</i> , "The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin", <i>Clin. Pharmacol. Ther.</i> , 60, 512-21 (1996)
	M. F. Fromm <i>et al.</i> , "Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs", in <i>Advanced Drug Delivery Reviews</i> , 27, 171-199 (1997)
	V. Ozdemir, <i>et al.</i> , "The Extent and Determinants of Changes in CYP2D6 and CYP1A2 Activities with Therapeutic Doses of Sertraline", <i>J. Clin. Psychopharm.</i> , 18, 55-61 (1998)
	S.E. Ball <i>et al.</i> , Venlafaxine: <i>in vitro</i> inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2", <i>Br. J. Pharm.</i> , 43, 619-26 (1997)
	A.D. Rodrigues, "The <i>In Vitro</i> Interaction of Dexmedetomidine with Human Liver Microsomal Cytochrome P4502D6", <i>Drug Metabolism and Disposition</i> , 25, 651-55 (1997)
T. Prueksaritanont <i>et al.</i> , " <i>In Vitro</i> and <i>In Vivo</i> Evaluations of Intestinal Barriers for the Zwitterion L-767,679 and its Carboxyl Ester Prodrug L-775,318, <i>Drug Metabolism and Disposition</i> , 26, 531-39 (1998)	
O.O. Simooya <i>et al.</i> , "Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians", <i>Br. J. Clin. Pharm.</i> , 45, 315-(1998);	
Sebastian Härtter <i>et al.</i> , "Inhibition of dextromethorphan metabolism by moclobemide", <i>Psychopharm.</i> , 135, 22-26 (1998)	

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	10/9/03
----------	--------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.